Conference Coverage
Conference Coverage
AI tool reveals MS drug interactions, offers safer options
Deep learning–based methods are “useful” in screening for potential interactions both between drugs and with foods.
Conference Coverage
Ocrelizumab benefit confirmed in older patients with MS
Lower rates of relapse were seen in older patients taking ocrelizumab, but the risk for relapse in this age group is low.
Conference Coverage
Obesity linked to multiple ills in MS study
Subjects with excess weight progressed more rapidly and had more cognitive disability.
Conference Coverage
DMT discontinuation trial halted; MS returned in 17.8%
It’s still not clear when – or if – certain patients should take a break from MS therapy.
Conference Coverage
Multiple sclerosis has a misdiagnosis problem
Experts warn that false-negative diagnoses cause treatment delays, while false-positive diagnoses run the risk for potential harm from needless...
Conference Coverage
No apparent drug interaction with ozanimod and antidepressants
Patients with MS who are taking SSRIs or SNRIs had lower rates of hypertension and adverse events potentially related to serotonin than patients...
Conference Coverage
‘Strikingly positive’ effect of novel MS agent
Frexalimab is a novel second-generation monoclonal antibody designed to block the costimulatory CD40/CD40L cellular pathway.
Conference Coverage
MS relapse rates similar between anti-CD20 mAbs and switching to fumarates
Although overall health care encounters did not statistically differ between patients who switched from anti-CD20 monoclonal antibodies to...
Conference Coverage
Shingles infection rates higher in patients with MS
Even among patients with MS who had no baseline immunosuppression from therapy, rates of herpes zoster infection were significantly higher than...
Conference Coverage
Ozanimod for relapsing MS shows long-term safety, efficacy with age differences
Urinary tract infections and other treatment-emergent adverse events increased with age, but respiratory infections were more common among...